NCT06754501: A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Cancer